258 related articles for article (PubMed ID: 34498666)
1. Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study).
Bonnot PE; Lintis A; Mercier F; Benzerdjeb N; Passot G; Pocard M; Meunier B; Bereder JM; Abboud K; Marchal F; Quenet F; Goere D; Msika S; Arvieux C; Pirro N; Wernert R; Rat P; Gagnière J; Lefevre JH; Courvoisier T; Kianmanesh R; Vaudoyer D; Rivoire M; Meeus P; Villeneuve L; Piessen G; Glehen O;
Br J Surg; 2021 Oct; 108(10):1225-1235. PubMed ID: 34498666
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis.
Bonnot PE; Piessen G; Kepenekian V; Decullier E; Pocard M; Meunier B; Bereder JM; Abboud K; Marchal F; Quenet F; Goere D; Msika S; Arvieux C; Pirro N; Wernert R; Rat P; Gagnière J; Lefevre JH; Courvoisier T; Kianmanesh R; Vaudoyer D; Rivoire M; Meeus P; Passot G; Glehen O;
J Clin Oncol; 2019 Aug; 37(23):2028-2040. PubMed ID: 31084544
[TBL] [Abstract][Full Text] [Related]
3. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
[TBL] [Abstract][Full Text] [Related]
4. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
Chia CS; You B; Decullier E; Vaudoyer D; Lorimier G; Abboud K; Bereder JM; Arvieux C; Boschetti G; Glehen O;
Ann Surg Oncol; 2016 Jun; 23(6):1971-9. PubMed ID: 26753751
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).
Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J
Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852
[TBL] [Abstract][Full Text] [Related]
6. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination.
Wu XJ; Yuan P; Li ZY; Bu ZD; Zhang LH; Wu AW; Zong XL; Li SX; Shan F; Ji X; Ren H; Ji JF
Tumour Biol; 2013 Feb; 34(1):463-9. PubMed ID: 23108893
[TBL] [Abstract][Full Text] [Related]
9. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.
Cornali T; Sammartino P; Kopanakis N; Christopoulou A; Framarino Dei Malatesta M; Efstathiou E; Spagnoli A; Ciardi A; Biacchi D; Spiliotis J
Ann Surg Oncol; 2018 Mar; 25(3):679-687. PubMed ID: 29282600
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness.
Gurusamy K; Vale CL; Pizzo E; Bhanot R; Davidson BR; Mould T; Mughal M; Saunders M; Aziz O; O'Dwyer S
BMJ Open; 2020 May; 10(5):e039314. PubMed ID: 32404398
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal hyperthermic chemotherapy after cytoreduction in patients with peritoneal metastases from endometrial cancer. The next frontier?
Navarro-Barrios Á; Gil-Martínez J; Ramos-Bernardo I; Barrios P; Muñoz-Casares C; Torres-Melero J; Pereira F; Manzanedo I; Arjona Á; Martínez-Regueira F; Cascales-Campos PA
Surg Oncol; 2020 Jun; 33():19-23. PubMed ID: 32561085
[TBL] [Abstract][Full Text] [Related]
13. Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials.
Green BL; Blumenthaler AN; Gamble LA; McDonald JD; Robinson K; Connolly M; Epstein M; Hernandez JM; Blakely AM; Badgwell BD; Davis JL
Ann Surg Oncol; 2023 Mar; 30(3):1852-1860. PubMed ID: 36348206
[TBL] [Abstract][Full Text] [Related]
14. Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus Surgery Without HIPEC for Goblet-Cell Carcinoids and Mixed Adenoneuroendocrine Carcinomas: Propensity Score-Matched Analysis of Centers in the Netherlands and Belgium.
Sluiter NR; van der Bilt JD; Croll DMR; Vriens MR; de Hingh IHJT; Hemmer P; Aalbers AGJ; Bremers AJA; Ceelen W; D'Hoore A; Schoonmade LJ; Coupé V; Verheul H; Kazemier G; Tuynman JB;
Clin Colorectal Cancer; 2020 Sep; 19(3):e87-e99. PubMed ID: 32651131
[TBL] [Abstract][Full Text] [Related]
15. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma.
Saxena A; Valle SJ; Liauw W; Morris DL
Anticancer Res; 2017 Oct; 37(10):5737-5742. PubMed ID: 28982894
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intraperitoneal chemotherapy for gastric cancer: a narrative review.
Chen C; Justo M; Gangi A
Chin Clin Oncol; 2023 Dec; 12(6):68. PubMed ID: 38195075
[TBL] [Abstract][Full Text] [Related]
17. Extremely high peritoneal cancer index in colorectal peritoneal metastases demonstrates safety and overall survival benefit in selected patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.
Ben-Yaacov A; Levine O; Schtrechman G; Adileh M; Beller T; Boursi B; Halpern N; Goldstein A; Ben-Yakov G; Nissan A; Laks S
World J Surg; 2024 Apr; 48(4):871-878. PubMed ID: 38686748
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis.
Rau B; Brandl A; Thuss-Patience P; Bergner F; Raue W; Arnold A; Horst D; Pratschke J; Biebl M
Gastric Cancer; 2019 Nov; 22(6):1226-1237. PubMed ID: 31065877
[TBL] [Abstract][Full Text] [Related]
19. Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?
Narasimhan V; Cheung F; Waters P; Peacock O; Warrier S; Lynch C; Michael M; Ramsay R; Heriot A
Surgeon; 2020 Oct; 18(5):287-294. PubMed ID: 31848069
[TBL] [Abstract][Full Text] [Related]
20. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?
Hotopp T
Surg Oncol; 2019 Mar; 28():159-166. PubMed ID: 30851894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
